SpringWorks Therapeutics (NASDAQ:SWTX) Trading 12.2% Higher

SpringWorks Therapeutics (NASDAQ:SWTX) traded up 12.2% during trading on Wednesday . The stock traded as high as $22.25 and last traded at $21.85, 124,600 shares were traded during mid-day trading. A decline of 19% from the average session volume of 154,777 shares. The stock had previously closed at $19.48.

A number of research firms have weighed in on SWTX. Goldman Sachs Group initiated coverage on SpringWorks Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $37.00 price target for the company. Wedbush initiated coverage on shares of SpringWorks Therapeutics in a report on Tuesday, October 8th. They issued an “outperform” rating and a $33.00 price objective on the stock. Cowen started coverage on shares of SpringWorks Therapeutics in a report on Tuesday, October 8th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of SpringWorks Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $32.00 target price for the company.

The firm has a 50 day moving average price of $19.27.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Tuesday, November 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($1.30). Equities analysts anticipate that SpringWorks Therapeutics will post -2.33 earnings per share for the current fiscal year.

In other news, major shareholder Bain Capital Life Sciences Inv bought 150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $2,700,000.00. Also, Director Stephen P. Squinto bought 275,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $4,950,000.00.

SpringWorks Therapeutics Company Profile (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

See Also: What is the Quick Ratio?

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.